PPI Products Must Warn Of Possible Increased Fracture Risk - FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA requires manufacturers to warn consumers that using proton pump inhibitors could increase the risk of some fractures, even though current research does not establish a causal link between the drug and fracture risk
You may also be interested in...
Liquid Rolaids Featured In Line’s Re-launch Into Crowded Antacid Market
Less than a year after Sanofi acquired Rolaids from Johnson & Johnson, its Chattem subsidiary reintroduces the antacid brand with tablet and liquid products in varying strengths. The liquid products could capitalize on Maalox and Mylanta missing from retail.
Liquid Rolaids Featured In Line’s Re-launch Into Crowded Antacid Market
Less than a year after Sanofi acquired Rolaids from Johnson & Johnson, its Chattem subsidiary reintroduces the antacid brand with tablet and liquid products in varying strengths. The liquid products could capitalize on Maalox and Mylanta missing from retail.
In Brief
FDA reverses on OTC PPI fracture risk